Press release
Endogenous Cushing's Syndrome Market to Reach USD 1.9 Billion by 2034
Endogenous Cushing's Syndrome
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72013
Globally, awareness campaigns, improved diagnostic tools, and novel therapies have accelerated market growth. With healthcare systems focusing on rare diseases and patient-centered care, the Endogenous Cushing's Syndrome Market is set to expand steadily from 2024 through 2034, driven by a blend of innovation and increasing disease recognition.
Market Overview
The global Endogenous Cushing's Syndrome Market size was valued at USD 1.2 billion in 2024 and is projected to reach USD 1.9 billion by 2034, growing at a CAGR of 5.0% over the forecast period . While the patient population remains relatively small compared to other endocrine disorders, the economic burden per patient is high due to long-term management requirements, hospitalizations, and the need for multi-disciplinary care.
Key Highlights:
• Base Year (2024): USD 1.2 billion
• Forecast Year (2034): USD 1.9 billion
• CAGR (2025-2034): 5.0%
• Growth Drivers: Increased awareness of rare diseases, expanding access to orphan drug therapies, and advancements in minimally invasive surgical techniques.
• Challenges: High treatment costs, misdiagnosis, delayed detection, and limited availability of skilled endocrinologists in emerging markets.
• Leading Players: Corcept Therapeutics, Novartis AG, HRA Pharma (subsidiary of Perrigo), Recordati Rare Diseases, and Strongbridge Biopharma.
Segmentation Analysis
By Product
• Steroidogenesis inhibitors (conazole, metyrapone, osilodrostat)
• Pituitary-directed therapies (pasireotide)
• Glucocorticoid receptor antagonists (mifepristone)
• Surgical interventions (transsphenoidal surgery, adrenalectomy)
• Supportive treatments (antihypertensives, antidiabetics, osteoporosis drugs)
By Platform
• Oral therapies
• Injectable therapies
• Surgical procedures
• Radiation therapy
By Technology
• Pharmacological drug development (novel receptor modulators, enzyme inhibitors)
• Imaging and diagnostic technologies (MRI, CT, PET scans)
• Surgical technologies (endoscopic transsphenoidal approaches)
By End Use
• Hospitals & specialty clinics
• Research institutes
• Ambulatory surgical centers
• Homecare (supportive treatment segment)
By Application
• Pituitary adenoma (Cushing's disease)
• Adrenal adenoma/carcinoma
• Ectopic ACTH syndrome
• Others (rare genetic causes)
Segmentation Summary:
The pharmacological segment dominates the market, with osilodrostat and pasireotide gaining prominence as first-line medical treatments, especially when surgery is not an option. Surgical intervention remains the gold standard for pituitary adenomas, but non-invasive therapies are rapidly growing due to higher recurrence rates post-surgery.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72013/endogenous-cushing-s-syndrome-market
Regional Analysis
North America
• Strong presence of leading biopharma companies.
• High healthcare expenditure on rare diseases.
• Favorable orphan drug legislations driving new product approvals.
Europe
• Increasing adoption of advanced imaging and diagnostic tools.
• Strong patient advocacy groups promoting early detection.
• Regulatory incentives supporting rare disease drug development.
Asia-Pacific
• Growing awareness among endocrinologists and healthcare professionals.
• Expanding healthcare infrastructure in countries like China and India.
• Rising investment by multinational pharmaceutical companies in rare disease markets.
Middle East & Africa
• Limited access to specialized endocrinologists and therapies.
• Dependence on imported medications.
• Gradual improvements in diagnostic services.
Latin America
• Emerging opportunities with improved healthcare access in Brazil and Mexico.
• Government initiatives to expand coverage for rare disease treatments.
Regional Summary:
North America leads the market due to robust R&D pipelines and early adoption of therapies, while Asia-Pacific represents the fastest-growing region thanks to improving healthcare infrastructure and growing disease awareness.
Market Dynamics
Growth Drivers
• Rising prevalence of rare endocrine disorders.
• Expanding orphan drug pipelines with regulatory incentives (priority reviews, tax benefits, exclusivity).
• Increasing demand for minimally invasive surgical and imaging techniques.
• Growing support from patient advocacy groups and non-profits.
Key Challenges
• High treatment and diagnostic costs, limiting patient access.
• Delayed or missed diagnoses due to overlapping symptoms with common conditions like obesity and diabetes.
• Adverse side effects of therapies, including hyperglycemia, adrenal insufficiency, and gastrointestinal disturbances.
Latest Trends
• Focus on precision medicine using genetic and molecular profiling.
• Development of long-acting formulations for better compliance.
• Integration of AI-driven diagnostic tools in radiology and pathology.
• Expansion of digital health platforms for monitoring cortisol levels and patient adherence.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72013
Competitor Analysis
Major Players:
• Corcept Therapeutics - leading with Korlym (mifepristone), a glucocorticoid receptor antagonist.
• Novartis AG - manufacturer of Signifor (pasireotide), widely used for pituitary tumors.
• Recordati Rare Diseases - key player with Isturisa (osilodrostat), recently approved in several markets.
• HRA Pharma (Perrigo) - active in steroidogenesis inhibitors.
• Strongbridge Biopharma - specializing in rare endocrine disorders.
• Other players: Teva Pharmaceuticals, Pfizer Inc., and niche biotech firms exploring novel ACTH inhibitors.
Competitive Dynamics:
The market is characterized by strong competition among rare-disease-focused pharma companies. Mergers, licensing deals, and collaborations with research institutes are common strategies. Recordati's Isturisa and Novartis's Signifor are establishing themselves as market leaders, while Corcept's focus on expanding indications for mifepristone reflects the ongoing race for market share.
Conclusion
The Endogenous Cushing's Syndrome Market, valued at USD 1.2 billion in 2024, is expected to reach USD 1.9 billion by 2034, reflecting a steady CAGR of 5.0%. This growth underscores the increasing focus on rare endocrine disorders, driven by innovation in therapies, enhanced diagnostic approaches, and supportive regulatory frameworks.
North America and Europe remain the dominant markets due to strong infrastructure and drug pipelines, but Asia-Pacific is emerging as the most promising growth hub. With evolving treatment paradigms, greater patient advocacy, and technological advances, the next decade will see more accessible and patient-friendly solutions.
Key Takeaways:
• Orphan drug development and supportive regulations are fueling market expansion.
• Pharmacological therapies, particularly osilodrostat and pasireotide, are reshaping treatment approaches.
• Precision medicine, AI-powered diagnostics, and global access programs represent the future of care.
By 2034, the Endogenous Cushing's Syndrome market will be more dynamic, innovation-driven, and globally inclusive, offering renewed hope for patients worldwide.
This report is also available in the following languages : Japanese (内因性クッシング症候群市場), Korean (내인성 쿠싱 증후군 시장), Chinese (内源性库欣综合征市场), French (Marché du syndrome de Cushing endogène), German (Markt für endogenes Cushing-Syndrom), and Italian (Mercato della sindrome di Cushing endogena), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72013/endogenous-cushing-s-syndrome-market#request-a-sample
Our More Reports:
Needle Free Drug Delivery Devices Market
https://exactitudeconsultancy.com/reports/73478/needle-free-drug-delivery-devices-market
Medical Device Labeling Market
https://exactitudeconsultancy.com/reports/73479/medical-device-labeling-market
Bone Cement Delivery System Market
https://exactitudeconsultancy.com/reports/73480/bone-cement-delivery-system-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endogenous Cushing's Syndrome Market to Reach USD 1.9 Billion by 2034 here
News-ID: 4188328 • Views: …
More Releases from Exactitude Consultancy
Cystinosis Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Cystinosis is a rare, inherited lysosomal storage disorder caused by the accumulation of cystine within cells, leading to progressive damage to multiple organs, including the kidneys, eyes, muscles, pancreas, and thyroid. If left untreated, it results in renal Fanconi syndrome, growth retardation, photophobia, and eventually kidney failure. The disease is typically diagnosed in infancy or early childhood, and without intervention, life expectancy is severely reduced.
Over the past two decades, cysteamine-based…
Somatotropin Deficiency Market Growth, Applications, Innovations and Business Ou …
Introduction
Somatotropin deficiency, commonly referred to as growth hormone deficiency (GHD), is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the pituitary gland. It manifests in children as stunted growth and delayed development, and in adults as metabolic issues, decreased bone density, and reduced quality of life. While congenital cases are often diagnosed in childhood, acquired forms may arise later in life due to trauma, tumors,…
Secondary Hyperparathyroidism Market Growth, Trends, Consumer Demand and Key Opp …
Introduction
Secondary hyperparathyroidism (SHPT) is a frequent and serious complication of chronic kidney disease (CKD), characterized by excessive secretion of parathyroid hormone (PTH) due to impaired calcium, phosphorus, and vitamin D metabolism. Left untreated, SHPT leads to mineral and bone disorders, cardiovascular complications, and poor quality of life for patients.
With the global CKD population rising sharply, particularly among patients on dialysis, the SHPT market has gained significant importance. Treatment approaches have…
Familial Amyloid Polyneuropathy (FAP) Market to Reach USD 2.4 Billion by 2034
Familial Amyloid Polyneuropathy (FAP) is a progressive, inherited rare disease caused by mutations in the transthyretin (TTR) gene, leading to the buildup of misfolded amyloid proteins in the peripheral nerves and multiple organs. This buildup causes nerve damage, autonomic dysfunction, and multi-system complications that, without treatment, can become life-threatening.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72015
In recent years, FAP has emerged as a critical focus area in the…
More Releases for Cushing
Cushing Syndrome Market Trends is Electrifying Growth Cycle: Bristol Myers Squib …
The latest study released on the Global Cushing Syndrome Market by HTF MI Research evaluates market size, trend, and forecast to 2031. The Cushing Syndrome market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key Players…
Cushing Syndrome Pipeline Appears Robust With 4+ Key Pharma Companies Actively W …
DelveInsight's, "Cushing Syndrome Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Cushing Syndrome…
Cushing Syndrome Market Is Booming So Rapidly | Recordati, Diurnal Group, Pfizer
The Global Cushing Syndrome Market Size is estimated at $1.4 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 22.6% to reach $8.8 Billion by 2034.
The latest study released on the Global Cushing Syndrome Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Cushing Syndrome market study covers significant research data and proofs to be a handy resource document for…
The Cushing’s Disease Treatment Market to grow at an invigorating pace in the …
Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal with injury or infection. Increasing levels of cortisol increases the blood sugar and can even cause diabetes mellitus. However the disease…
Somatostatin Analogs Market Report 2018: Segmentation by Product (Octreotide, La …
Global Somatostatin Analogs market research report provides company profile for Chiasma, Ipsen Biopharmaceutical, Novartis, Peptron and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation on the basis of…
Cushing’s Disease Treatment Market Forecast over 2017 – 2025
Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal with injury or infection. Increasing levels of cortisol increases the blood sugar and can even cause diabetes mellitus. However the disease…
